Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Emilia Dominguez Recio"'
Autor:
Nuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, Sofía Ruiz-Medina, Javier Garcia-Corbacho, Jose Carlos Benitez, Maria Emilia Dominguez-Recio, Esperanza Torres, Lucia Oliva, Manuel Zalabardo, Antonio Rueda, Emilio Alba
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEData from population-based studies have shown an increased incidence of certain types of neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived from other real-world data sources. In a no
Externí odkaz:
https://doaj.org/article/9cade2a971ce489fb67e02e30bfa5fa6
Autor:
Bernardo Herrera Imbroda, Maria Emilia Dominguez Recio, Julia Diaz Crespo, Angela M. Soriano Perez, Jose Cruz Mañas, Aida Raigon Ponferrada, Marta Ramirez Aliaga, Ana Fontaneda Heredia, Manuel Rubio Navarro, Alicia Ramirez Fernandez, Alfredo Malo Manso, Jose Luis Guerrero Orriach, Juan Jose Escalona Belmonte
Publikováno v:
Oncology. 98:161-167
Background:The effect of anesthetic techniques on cancer recurrence has been the subject of intensive research in the past years, as it affects a large proportion of the population. The use of opioids and halogenated agents in cancer patients during
Autor:
Alfonso Alba-Bernal, Rocío Lavado-Valenzuela, María Isabel Queipo-Ortuño, Maria Emilia Dominguez-Recio, Iñaki Comino-Méndez, Emilio Alba, Begoña Jimenez-Rodriguez
Publikováno v:
EBioMedicine, Vol 62, Iss, Pp 103100-(2020)
EBioMedicine
EBioMedicine
Breast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumou
Autor:
Emilio Alba, Maria Emilia Dominguez-Recio, Aurora Laborda-Illanes, Rocío Lavado, María Isabel Queipo-Ortuño, Lidia Sánchez-Alcoholado, Begoña Jimenez-Rodriguez, Iñaki Comino-Méndez
Publikováno v:
Cancers, Vol 12, Iss 2465, p 2465 (2020)
Cancers
Cancers
Simple Summary In this review we discuss the recent knowledge about the role of breast and gut microbiome in the pathogenesis of breast cancer. We examine the proposed mechanisms of interaction between breast tumors and the microbiome. We focus on th
Autor:
Maria Emilia Dominguez Recio, Marta Ramirez Aliaga, Francisco J F García, Jose Cruz-Mañas, Alfredo Malo-Manso, J J Escalona-Belmonte, Jose Luis Guerrero-Orriach, Emilio A Conejo, Aida Raigon-Ponferrada, Alicia Ramirez Fernandez
Publikováno v:
Current pharmaceutical design. 25(28)
Breast cancer is a complex heterogeneous disease that is categorized into several histological and genomic subtypes with relevant prognostic and therapeutical implications. Such diversity requires a multidisciplinary approach for a comprehensive trea
Autor:
María José Bermejo-Pérez, Isaac Plaza-Andrades, Lidia Sánchez-Alcoholado, Maria Emilia Dominguez-Recio, Alicia González-González, Soukaina Boutriq, Rocío Lavado-Valenzuela, María Isabel Queipo-Ortuño, Emilio Alba, Aurora Laborda-Illanes, Jesús Peralta-Linero
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 659, p 659 (2021)
Journal of Personalized Medicine
Journal of Personalized Medicine
Endometrial cancer is one of the most common gynaecological malignancies worldwide. Histologically, two types of endometrial cancer with morphological and molecular differences and also therapeutic implications have been identified. Type I endometria
Autor:
Bella Pajares, Alfonso Sánchez-Muñoz, Héctor Mesa, Tamara Diaz Redondo, José M. Jerez, Enrique Saez Lara, Antonia Márquez, Ester Villar, Francisco Carabantes, Sofía Ruíz, Emilio Alba, Pablo Rodriguez-Brazzarola, Laura Galvez Carvajal, Maria-Jose Bermejo-Perez, Maria Emilia Dominguez-Recio, Irene López, Ana Godoy, Nuria Ribelles, Leo Franco, Begona Jimenez Rodriguez
Publikováno v:
Journal of Clinical Oncology. 38:e13040-e13040
e13040 Background: The treatment of luminal MBC has undergone a substantial change with the use of cyclin dependent kinase 4/6 inhibitors (CDKIs). Nevertheless, there is not a clearly defined subgroup of patients who do not initially respond to CDKIs
Autor:
Sofía Ruíz, Vanessa de Luque, Tamara Diaz Redondo, Nuria Ribelles, Encarnación González Flores, Marta Robles-Lasarte, Maria Emilia Dominguez-Recio, José M. Jerez, Alfonso Sánchez-Muñoz, Jose Antonio Lopez-Lopez, Enrique Saez Lara, Francisco Carabantes, José Manuel Baena-Cañada, Jesus Perales-Adan, Martina Alvarez, Ana Godoy, Emilio Alba, Ester Villar, Rocío Lavado-Valenzuela, Cristina Morales-Estevez
Publikováno v:
Journal of Clinical Oncology. 38:e13035-e13035
e13035 Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of hormone receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with improvement in PFS consistently demonstrated in sev